Silver coatings to combat catheter associated infections

银涂层可对抗导管相关感染

• 批准号: 7049688
• 负责人: BRUCE L GIBBINS
• 金额: $ 14.37万
• 依托单位: ACRYMED, INC.
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-02-01 至 2006-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7049688
• 关键词: antiinfective agents; biofilm; biomaterial compatibility; biomaterial development /preparation; biomedical equipment development; cell mediated lymphocytolysis test; cell proliferation; chemical synthesis; disease /therapy duration; fibroblasts; growth inhibitors; human tissue; keratinocyte; nosocomial infection control; polymers; silicon compounds; silver; slow release drug; surface coating; tissue /cell culture; urinary catheterization

DESCRIPTION (provided by applicant): Abstract Indwelling catheterization is a leading cause of nosocomial infections that present an enormous drain of health care funding in the US. Clinical infections associated with urinary catheterization have been estimated to add more than $1000 to patient care. Those that occur with central venous catheterization escalate the cost to between $35,000 and $50,000 per infection, with a mortality rate that exceeds 35%. The incorporation of antimicrobiotics and antiseptics into catheter materials in order to reduce the rate of associated infections has been investigated for the past thirty years with limited success. In particular, it has been difficult to demonstrate that antimicrobial catheters provide a significant clinical benefit when used for long-term catheterization (> 1 week). The main limitation has been to obtain a sufficient sustained release of the antimicrobial agent to prevent the colonization and biofilm formation that serves as a reservoir for infecting microbes. We have developed a stabilized sustained release silver reservoir that has proven to be highly effective in prolonging the antimicrobial activity in a number of wound care products. Preliminary studies have shown that this technology is adaptable for use in hydrophobic silicone materials, and treated catheters can inhibit microbial growth and biofilm formation for at least 10 days. This project is intended to confirm and extend our initial observations with the aim of perfecting a technology for improving catheters. Successful commercialization would significantly improve catheter design and contribute to a reduction in health care expenditure for nosocomial infections.

描述（由申请人提供）：摘要留置导尿管是医院感染的主要原因，导致美国医疗保健资金大量流失。据估计，与导尿相关的临床感染将导致患者护理费用增加 1000 多美元。中心静脉导管插入术导致的每次感染费用高达 35,000 至 50,000 美元，死亡率超过 35%。在过去的三十年里，人们对在导管材料中加入抗生素和防腐剂以降低相关感染率进行了研究，但取得的成功有限。特别是，很难证明抗菌导管在用于长期导尿（> 1 周）时能提供显着的临床益处。主要的限制是获得足够的抗菌剂持续释放以防止作为感染微生物的储存库的定殖和生物膜形成。我们开发了一种稳定的缓释银储库，已被证明在延长许多伤口护理产品的抗菌活性方面非常有效。初步研究表明，该技术适用于疏水性有机硅材料，经处理的导管可抑制微生物生长和生物膜形成至少10天。该项目旨在确认和扩展我们的初步观察结果，旨在完善改进导管的技术。成功的商业化将显着改善导管设计，并有助于减少医院感染的医疗保健支出。